6H-5,22-iminopyrido[3,2-k][8,2,9,16]-benzothiatriazacyclononadecine-14,21-dione,16-fluoro-8,9,10,11,12,13,19,20-octahydro-23-hydroxy-6-methyl-7,7-dioxide | 1292210-93-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: 6H-5,22-iminopyrido[3,2-k][8,2,9,16]-benzothiatriazacyclononadecine-14,21-dione,16-fluoro-8,9,10,11,12,13,19,20-octahydro-23-hydroxy-6-methyl-7,7-dioxide
• 英文别名: 8-Fluoro-27-hydroxy-19-methyl-18,18-dioxo-18lambda6-thia-3,12,19,25,28-pentazatetracyclo[18.7.1.05,10.021,26]octacosa-1(27),5(10),6,8,20(28),21(26),22,24-octaene-2,11-dione；8-fluoro-27-hydroxy-19-methyl-18,18-dioxo-18λ6-thia-3,12,19,25,28-pentazatetracyclo[18.7.1.05,10.021,26]octacosa-1(27),5(10),6,8,20(28),21(26),22,24-octaene-2,11-dione
• CAS: 1292210-93-5
• 化学式: C₂₃H₂₄FN₅O₅S
• 分子量: 501.538
• InChiKey: LKLWVPSCSCVWGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  35
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  150
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2-氯-3-吡啶甲醛 在 盐酸 、 2,2'-联吡啶 、 N-溴代丁二酰亚胺(NBS) 、 copper(l) iodide 、 1,3-双(二苯基膦)丙烷 、 水 、 sodium ethanolate 、 palladium diacetate 、 三乙酰氧基硼氢化钠 、 potassium carbonate 、 溶剂黄146 、 1-丙基磷酸酐 、 三乙胺 、 N,N-二异丙基乙胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 100.0 ℃ 、517.12 kPa 条件下， 反应 93.0h， 生成 6H-5,22-iminopyrido[3,2-k][8,2,9,16]-benzothiatriazacyclononadecine-14,21-dione,16-fluoro-8,9,10,11,12,13,19,20-octahydro-23-hydroxy-6-methyl-7,7-dioxide
  参考文献：
  名称：

  Copper-Catalyzed C–N Coupling in the Synthesis of Integrase Inhibitors of Immunodeficiency Viruses

  摘要：

  This contribution describes the total synthesis of a complex macrocyclic integrase inhibitor, a key enzyme involved in the infection process of various immunodeficiency viruses. The key transformation of the synthetic strategy was the selective C-N coupling of a sulfonamide to a heteroaryl bromide in the presence of potentially competing amide and carbamate functionalities. The transformation was accomplished with CuI catalysis using bypiridine as the ligand in the presence of base and enabled a convergent approach to the target molecule.

  DOI：

  10.1021/op400228z

文献信息

• [EN] MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS<br/>[FR] INHIBITEURS D'INTÉGRASE MACROCYCLIQUES POUR UTILISATION DANS LE TRAITEMENT DU VIRUS DE L'IMMUNODÉFICIENCE FÉLINE
  申请人：ELANCO ANIMAL HEALTH IRELAND

  公开号：WO2012112345A1

  公开（公告）日：2012-08-23

  This invention concerns to naphthyridin derivatives of formula (I) for use in the treatment or prevention of feline immunodeficiency virus (FIV). Furthermore the present invention relates to a method of treating or preventing infection of feline immunodeficiency virus in a feline animal wherein said method comprises the administration to said feline animal of a therapeutically effective amount of a naphthyridin derivative.

  这项发明涉及到式(I)的萘啉衍生物，用于治疗或预防猫免疫缺陷病毒（FIV）。此外，本发明涉及一种治疗或预防猫免疫缺陷病毒感染的方法，其中所述方法包括向所述猫动物施用有效治疗量的萘啉衍生物。
• Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus
  申请人：Elanco Animal Health Ireland Limited

  公开号：EP2487176A1

  公开（公告）日：2012-08-15

  This invention concerns to naphthyridin derivatives of formula (I) for use in the treatment or prevention of feline immunodeficiency virus (FIV). Furthermore the present invention relates to a method of treating or preventing infection of feline immunodeficiency virus in a feline animal wherein said method comprises the administration to said feline animal of a therapeutically effective amount of a naphthyridin derivative.

  这项发明涉及一种用于治疗或预防猫免疫缺陷病毒（FIV）的式（I）的萘啶衍生物。此外，本发明涉及一种治疗或预防猫免疫缺陷病毒感染的方法，其中该方法包括向该猫动物投予一种萘啶衍生物的治疗有效量。
• [EN] MACROCYCLIC INTEGRASE INHIBITORS<br/>[FR] INHIBITEURS MACROCYCLIQUES D'INTÉGRASE
  申请人：TIBOTEC PHARM LTD

  公开号：WO2011045330A1

  公开（公告）日：2011-04-21

  Compound having formula (I), wherein - W is NH-, -N(CH3)- or piperazine, - X is a bond, -C(=O)- or S(=O)2-, - Y is C3-7alkylene, and - Z is NH-C(=O)- or -O-, and pharmaceutically acceptable salts thereof, their pharmaceutical formulations and use as HIV inhibitors.

  具有化学式（I）的化合物，其中- W为NH-，-N(CH3)-或哌嗪，- X为键，-C(=O)-或S(=O)2-，- Y为C3-7烷基，- Z为NH-C(=O)-或-O-，以及其药学上可接受的盐，它们的药物配方以及用作HIV抑制剂。
• MACROCYCLIC INTEGRASE INHIBITORS
  申请人：Thuring Johannes Wilhelmus J

  公开号：US20120172367A1

  公开（公告）日：2012-07-05

  Compound having formula (I), wherein —W is NH—, —N(CH 3 )— or piperazine, —X is a bond, —C(═O)— or S(═O) 2 —, —Y is C 3-7 alkylene, and —Z is NH—C(═O)— or —O—, and pharmaceutically acceptable salts thereof, their pharmaceutical formulations and use as HIV inhibitors.

  具有式(I)的化合物，其中-W是NH-，-N(CH3)-或哌嗪，-X是键，-C(═O)-或S(═O)2-，-Y是C3-7烷基，-Z是NH-C(═O)-或-O-，以及其药学上可接受的盐，其制药配方和用作HIV抑制剂。
• MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS
  申请人：Thuring Johannes Wilhelmus J.

  公开号：US20130296330A1

  公开（公告）日：2013-11-07

  This invention concerns to naphthyridin derivatives of formula (I) for use in the treatment or prevention of feline immunodeficiency virus (FIV). Furthermore the present invention relates to a method of treating or preventing infection of feline immunodeficiency virus in a feline animal wherein said method comprises the administration to said feline animal of a therapeutically effective amount of a naphthyridin derivative.

  本发明涉及式（I）的萘啶衍生物，用于治疗或预防猫免疫缺陷病毒（FIV）。此外，本发明还涉及一种治疗或预防猫动物感染猫免疫缺陷病毒的方法，其中所述方法包括向所述猫动物施用萘啶衍生物的治疗有效量。